To date, in appropriate patients, somatostatin analogs are the only proven therapy for the management of hormonal symptoms resulting from NETs. In addition, some studies have shown that somatostatin analog treatment may also help to stabilize disease in patients with NETs. Clinical trials with somatostatin analogs have shown that they have antiproliferative properties which can stop the growth of cancer cells, confirming their benefit for patients with well-differentiated advanced disease.
Administration of Lanreotide
The route of administration of the lanreotide gel formulation is via deep subcutaneous (under the skin) injection.
Administration of Octreotide
The route of administration is usually via one of three different routes: subcutaneous (just under the skin) injection; continuous subcutaneous infusion delivered with the use of a pump; and a long-acting, slow release formulation delivered intramuscularly. Each option has advantages and disadvantages, which your doctor can discuss with you.
Since the immediate-release form of octreotide remains active in the body for only a very short time, long-acting release (LAR) formulations have been developed to allow some patients to receive a deep subcutaneous or intramuscular injection only once per month. LAR formulations of octreotide and lanreotide are now considered the “standard of care”. Treatment is always modified to meet the patient’s specific needs, based on the recurrence of symptoms (if any) and the results of hormone level testing.